Literature DB >> 2503935

Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease.

E Berntorp1, I M Nilsson.   

Abstract

In previous studies, we have found Hemate P (Behring) to be the only commercial virus-inactivated high-purity factor VIII concentrate that contains native von Willebrand factor. In the present study, Hemate P was given to 7 patients with the severe recessive form of von Willebrand's disease, to 2 patients with type Ia, to 1 patient with type IIB, and to 1 patient with type IIC von Willebrand's disease. A correction of the hemostatic defect was seen in all patients. Satisfactory hemostasis was also obtained in clinical situations, 1 patient undergoing major surgery and another being delivered, both without undue loss of blood. We conclude that Hemate P is an efficacious and safe product for use in cases of von Willebrand's disease when pharmacological correction of the hemostatic defect is not possible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503935     DOI: 10.1111/j.1423-0410.1989.tb02031.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

2.  Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.

Authors: 
Journal:  P T       Date:  2010-01

Review 3.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

4.  Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

Authors: 
Journal:  CMAJ       Date:  1995-07-15       Impact factor: 8.262

5.  Spontaneous iliopsoas muscle hematoma in a patient with von Willebrand disease: a case report.

Authors:  Bijan Keikhaei; Ahmad Soltani Shirazi
Journal:  J Med Case Rep       Date:  2011-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.